Synthetic lincosamides iboxamycin and cresomycin are active against ocular multidrug-resistant methicillin-resistant S. aureus carrying erm genes.

Antimicrobial resistance is a global pandemic that poses a major threat to vision health as ocular bacteria, especially methicillin-resistant S. aureus (MRSA), are becoming increasingly resistant to first-line therapies. Here we evaluated the antimicrobial activity of new synthetic lincosamides in comparison to currently used antibiotics against clinical ocular MRSA isolates. Antimicrobial susceptibility testing was performed by broth microdilution for two novel synthetic lincosamides (iboxamycin and cresomycin) and 8 comparator antibiotics against a collection of 50 genomically characterized ocular MRSA isolates, including isolates harboring erm genes (n=25). Both drugs were active against widespread MRSA clonal complexes CC8 and CC5. The MIC Our results demonstrate that iboxamycin and cresomycin display potent in vitro activity against ocular MRSA isolates, including multidrug-resistant isolates harboring erm genes.

Informations de copyright

Copyright © 2024. Published by Elsevier Ltd.

Déclaration de conflit d'intérêts

Declaration of competing interest KJYW and AGM have filed international patent application WO/2023/205206, “Lincosamides and Uses Thereof.”